Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes

International Journal of Endocrinology
Bing-Li LiuJian-Hua Ma

Abstract

To compare the effect of the rapid-acting insulin analogues (RAIAs) aspart (NovoRapid) and lispro (Prandilin) on glycemic variations by continuous glucose monitoring system (CGMS) in patients within newly diagnosed type 2 diabetes mellitus (T2DM) receiving continuous subcutaneous insulin infusion (CSII) and metformin intensive therapy. This is a single-blind randomized controlled trial. A total of 110 patients with newly diagnosed T2DM and with hemoglobin A1c (HbA1c%) above 9% was hospitalized and randomly divided into two groups: group Asp (NovoRapid group) and group Lis (Prandilin group). They all received CSII and metformin therapy. Treatments were maintained for 2-3 weeks after the glycaemic target was reached. C-peptide and insulin and fructosamine were determined. CGMS was continuously applied for 4 days after reaching the glycemic target. There were no significant differences in daily dosages of insulin, fasting plasma C-P and 2 h postprandial C-P and insulin, and fructosamine at the baseline and endpoint between the groups Asp and Lis. No significant differences were seen in the 24 h mean amplitude of glycemic excursions (MAGE), 24 h mean blood glucose (MBG), the standard deviation of the MBG (SDBG), fasting blood gluco...Continue Reading

References

Aug 26, 1998·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·A ReichelJ Schulze
May 25, 2002·BMJ : British Medical Journal·Howard A WolpertMyra A Lipes
Jan 9, 2003·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·M-A von MachJ Beyer
Jul 2, 2003·Diabetes Care·Carol HomkoGuenther Boden
Sep 10, 2005·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·R H A BeckerH Scholtz
Jun 28, 2006·Diabetes Technology & Therapeutics·Michael R DeFelippisSacha M Storms
Jul 11, 2006·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·R P Hoogma, D Schumicki
Jun 27, 2007·Diabetes, Obesity & Metabolism·T HeiseR H A Becker
Oct 11, 2007·Diabetes, Obesity & Metabolism·O SchnellUNKNOWN Acarbose-Insulin Combination Study Group
Nov 24, 2007·Diabetes Technology & Therapeutics·Jakob SenstiusAage Hvass
Jan 1, 2008·Diabetes Research and Clinical Practice·Stephen LuzioDavid R Owens
Apr 30, 2010·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·S ArnoldsT Heise
Nov 6, 2014·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·James ThrasherLeonard C Glass
Apr 14, 2015·Diabetes/metabolism Research and Reviews·Paolo PozzilliEric Renard
Feb 4, 2016·Journal of Diabetes Research·Feng-Fei LiJian-Hua Ma
Jul 1, 2016·The Cochrane Database of Systematic Reviews·Birgit FullertonFerdinand M Gerlach

❮ Previous
Next ❯

Citations

Jan 12, 2020·Journal of Basic and Clinical Physiology and Pharmacology·Arina D PuspitasariBudi Suprapti

❮ Previous
Next ❯

Software Mentioned

CGMS

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.